ULIPRISTAL ACETATE

(ULIPRISTALI ACETAS)

Draft proposal for inclusion for The International Pharmacopoeia

(July 2021)

DRAFT FOR COMMENTS

Please send any comments you may have on this draft working document to Dr Herbert Schmidt, Technical Officer, Norms and Standards for Pharmaceuticals, Technical Standards and Specifications (schmidt@who.int), with a copy to Ms Sinéad Jones (jonessi@who.int) by 3 September 2021.

Our working documents are sent out electronically and they will also be placed on the WHO Medicines website (https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/pharmaceuticals/current-projects) for comments under the “Working documents in public consultation” link. If you wish to receive our draft guidelines, please send your e-mail address to jonessi@who.int and your name will be added to our electronic mailing list.

© World Health Organization 2021

All rights reserved.

This is a draft. The content of this document is not final, and the text may be subject to revisions before publication. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization.

Please send any request for permission to: Ms Sinéad Jones, Norms and Standards for Pharmaceuticals, Technical Standards and Specifications, Department of Health Products Policy and Standards, World Health Organization, CH-1211 Geneva 27, Switzerland, email: jonessi@who.int.

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft.

However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.
SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/21.870:

ULIPRISTAL ACETATE
(ULIPRISTALI ACETAS)

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monograph drafted based on information received from a manufacturer.</td>
<td>January 2021</td>
</tr>
<tr>
<td>Laboratory investigations to verify and validate the analytical provisions.</td>
<td>February – June 2021</td>
</tr>
<tr>
<td>Monograph sent out for public consultation.</td>
<td>July – August 2021</td>
</tr>
<tr>
<td>Further follow-up action as required.</td>
<td></td>
</tr>
</tbody>
</table>

[Note from the Secretariat. It is proposed to include a monograph on Ulipristal acetate in The International Pharmacopoeia. The draft monograph is based on information provided by a manufacturer and on laboratory investigations.]
ULIPRISTAL ACETATE (ULIPRISTALI ACETAS)

Molecular formula. $C_{30}H_{37}NO_4$

Relative molecular mass. 475.63

Graphic formula.


Description. A white to yellowish crystalline powder

Solubility. Freely soluble in dichloromethane R; soluble in methanol R, acetone R and ethanol, dehydrated, R; practically insoluble in water.

Category. Oral hormonal contraceptive.

Storage. Ulipristal acetate should be kept in a well-closed container, protected from light.

Additional information. Ulipristal acetate exhibits polymorphism.

Requirements

Definition. Ulipristal Acetate contains not less than 98.0% and not more than 102.0% of $C_{30}H_{37}NO_4$, calculated with reference to the anhydrous substance.
Identity tests

- Either test A alone, or any two of tests B, C or D may be applied.

A. Carry out the test as described under 1.7 Spectrophotometry in the infrared region. The infrared absorption spectrum is concordant with the spectrum obtained from ulipristal acetate RS.

If the spectra thus obtained are not concordant, repeat the test using the residues obtained by separately dissolving the test substance and ulipristal acetate RS in a small amount of dehydrated ethanol R and evaporating to dryness. The infrared absorption spectrum is concordant with the spectrum obtained from ulipristal acetate RS.

B. Carry out the test as described under 1.14.4 High-performance liquid chromatography using the conditions given under “Assay”, Method A. The retention time of the principal peak in the chromatogram obtained with solution (1) corresponds to the retention time of the peak due to ulipristal acetate in the chromatogram obtained with solution (2).

C. The absorption spectrum (1.6 Spectrophotometry in the visible and ultraviolet regions) of a 0.03 mg per mL solution of the test substance in methanol R, when observed between 230 nm and 400 nm, exhibits maxima at about 262 nm and 302 nm.

Alternatively, in combination with identity test B, where a diode-array detector is available, record the UV spectrum of the principal peak in the chromatograms with a diode array detector in the range of 230 nm to 400 nm. The UV spectrum of the principal peak in the chromatogram obtained with solution (1) corresponds to the UV spectrum of the peak due to ulipristal acetate in the chromatogram obtained with solution (2).
D. Carry out test D.1 or, where UV detection is not available, test D.2.

D.1 Carry out the test as described under 1.14.1 Thin-layer chromatography using silica gel R6 as the coating substance and a freshly prepared mixture of 2 volumes of ethyl acetate R and 8 volumes of dichloromethane R as the mobile phase. Apply separately to the plate 2 µL of each of the following two solutions in dehydrated ethanol R, containing (A) 6 mg of the test substance per mL and (B) 6 mg of ulipristal acetate RS per mL.

After removing the plate from the chromatographic chamber, allow it to dry in air. Then heat the plate for 5 minutes in an oven at 100 °C. Examine the chromatogram under ultraviolet light (254 nm).

The principal spot in the chromatogram obtained with solution (A) corresponds in position, appearance and intensity with the spot due to ulipristal acetate in the chromatogram obtained with solution (B).

D.2 Carry out the test as described under 1.14.1 Thin-layer chromatography using silica gel R5 as the coating substance and the conditions as described above under test D.1. Spray the plate with a 100 g/L solution of phosphomolybdic acid R in dehydrated ethanol R. Heat the plate at 100 °C in an oven until spots appear (for about 5 minutes). Examine the chromatogram under visible light. The principal spot in the chromatogram obtained with solution (A) corresponds in position, appearance and intensity with the spot due to Ulipristal acetate in the chromatogram obtained with solution (B).

Specific optical rotation (I.4). Use a 10 mg per mL solution of the test substance in dioxane R. Calculate with reference to the anhydrous substance; the specific optical rotation \([\alpha]_{D}^{20}\) is between +156 to +159.

Sulfated ash (2.3). Not more than 1.0 mg/g, determined on 1.0 g.
**Water.** Determine, as described under 2.8 *Determination of water by the Karl Fischer method*, Method A. Use 0.500 g of the test substance. The water content is not more than 5 mg/g.

**Heavy metals.** Use 0.30 g for the preparation of the test solution as described under 2.2.3 *Limit test for heavy metals*, Procedure 5; determine the heavy metals content according to Method C; not more than 10 μg/g.

**Related substances.** Perform the test using low-actinic glassware. Carry out the test as described under 1.14.4 *High-performance liquid chromatography* using the conditions given below under “Assay”, Method A, with the following modifications.

Prepare the following solution in mobile phase: For solution (1), dissolve 30.0 mg of the test substance in 20 mL using sonification and dilute to 50.0 mL. For solution (2), dilute 1.0 mL of solution (1) to 200.0 mL. For solution (3), dilute 2.0 mL of solution (2) to 20.0 mL. For solution (4), prepare a solution containing 0.6 mg/mL ulipristal acetate RS and 0.03 mg/mL ulipristal acetate impurity A RS.

Inject alternately 10 μL each of solutions (1), (2), (3) and (4).

The impurities are eluted, if present, at the following relative retentions with reference to ulipristal acetate (retention time about 9.1 minutes): impurity B about 0.66; impurity C about 0.87 and impurity A about 1.05.

The test is not valid unless, in the chromatogram obtained with solution (4), the resolution between the peaks due to ulipristal acetate and impurity A is at least 1.3. Also, the test is not valid unless in the chromatogram obtained with solution (3) the signal-to-noise ratio of the peak due to ulipristal acetate is at least 10.

In the chromatogram obtained with solution (1):
the area of any peak corresponding to impurity B is not greater than 1.6 times
the area of the peak due to ulipristal acetate in the chromatogram obtained
with solution (2) (0.8 %);

- the area of any peak corresponding to impurity C is not greater than 0.3 times
the area of the peak due to ulipristal acetate in the chromatogram obtained
with solution (2) (0.15 %);

- the area of any other impurity peak is not greater than 0.2 times the area of
the peak due to ulipristal acetate in the chromatogram obtained with solution
(2) (0.10 %).

- The sum of the areas of all impurity peaks is not greater than twice the area
of the peak due to ulipristal acetate in the chromatogram obtained with
solution (2) (1.0%). Disregard all peaks with an area of less than the area of
the peak due to ulipristal acetate in the chromatogram obtained with solution
(3) (0.05%).

Assay

- Either test A or test B may be applied.

A. Perform the test using low-actinic glassware. Carry out the test as described
under 1.14.4 High-performance liquid chromatography using a stainless steel
column (4.6 mm x 25 cm) packed with particles of silica gel, the surface of
which has been modified with chemically-bonded octadecylsilyl groups (5
µm).1

Prepare a phosphate buffer by dissolving 4.76 g of potassium dihydrogen
phosphate R in 1000 mL of water R. Adjust the pH to 7.0 with triethylamine
R. As the mobile phase, use a mixture of 40 volumes of acetonitrile R, 15
volumes of tetrahydrofuran R and 45 volumes of the phosphate buffer.

---

1A Hichrom Apex ODS column has been found suitable.
Operate with a flow rate of 1.0 mL per minute.

As a detector, use an ultraviolet spectrophotometer set at a wavelength of 254 nm.

Prepare the following solutions in mobile phase: For solution (1), dissolve 30.0 mg of the test substance in 20 mL using sonication and dilute to 50.0 mL. For solution (2), dissolve 30.0 mg of ulipristal acetate RS in 20 mL using sonication and dilute to 50.0 mL.

Inject alternately 10 µL each of solutions (1) and (2) and record the chromatogram for 2.5 times the retention time of ulipristal acetate.

Measure the areas of the peaks corresponding to ulipristal acetate obtained in the chromatograms of solutions (1) and (2) and calculate the percentage content of C\textsubscript{30}H\textsubscript{37}NO\textsubscript{4} in the sample, using the declared content of C\textsubscript{30}H\textsubscript{37}NO\textsubscript{4} in ulipristal acetate RS.

B. Dissolve 150.0 mg of the test substance in sufficient methanol R and dilute to 100.0 mL with the same solvent. Dilute 5.0 mL of this solution to 250.0 mL with methanol R. Measure the absorbance as described under 1.6 Spectrophotometry in the visible and ultraviolet regions of the resulting solution in a cuvette with an optical pathlength of 10 mm at the maximum of about 302 nm.

Calculate the percentage content of C\textsubscript{30}H\textsubscript{37}NO\textsubscript{4} in the sample, using the absorptivity value of 48.5 for ulipristal acetate (A\textsubscript{1%}\textsubscript{cm} = 484).

Impurities


C. 11β-[4-(Dimethylamino)phenyl]-(2'R)-5'-methyl-3'H-spiro[norandrosta-4,9-diene-17,2'furan]3,3'-dione; (ulipristal cyclopentenone analogue).
Reference substances to be established

Ulipristal acetate impurity A RS

- New International Chemical Reference Substance to be established.

Ulipristal acetate RS

- New International Chemical Reference Substance to be established.

***